Skip to main content
. 2014 Jan 13;2014(1):CD003559. doi: 10.1002/14651858.CD003559.pub4

3.

3

In the control group, 21 of 100 people with moderate or severe asthma were able to withdraw from treatment with inhaled corticosteroids completely (over a 28‐ to 32‐week period) compared with 40 (95% CI 35 to 46) of 100 for the omalizumab group with tapering corticosteroids.